Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Krystal Biotech reports robust Q3 earnings and eyes global expansion

Krystal Biotech's Q3 performance showcased positive earnings and high patient conversion rates.
Despite challenges in patient source diversity and conversion cycle, the company remains well-positioned.
Opportunities lie in global expansion, pipeline advancement, and leadership enhancements.
Overall, Krystal Biotech's strong financials and patient compliance bode well for future growth.

Krystal Biotech excels with VYJUVEK, eyes global expansion

Krystal Biotech's VYJUVEK shows strong performance and market potential
Balanced financials and strategic clinical trials position for future growth
Challenges include competitive landscape shifts and global expansion execution
Opportunities lie in market expansion, pipeline advancements, and partnerships

Krystal Biotech excels in Q1 2024, eyes global expansion

Krystal Biotech's strong performance in Q1 2024 reflects continued growth and execution.
The company's focus on compliance, pipeline advancements, and global expansion positions it well.
Challenges in conversion time and reimbursement delays require strategic mitigation.
Opportunities in European and Japanese markets, patient education, and new product data.

Krystal Biotech excels in Q2 2024, eyes global expansion

Krystal Biotech's Q2 2024 performance reflects strong revenue growth, profitability, and operational efficiency, positioning the company well for future success.
The company's focus on patient demand, compliance, and global expansion highlights its strategic priorities and growth trajectory.
While facing challenges in manufacturing expansion and clinical data readouts, Krystal Biotech has opportunities to drive revenue growth and market expansion through strategic initiatives.

Krystal Biotech excels in Q3 with VYJUVEK success and global expansion plans

Krystal Biotech's Q3 performance reflects strong revenue growth, profitability, and strategic advancements in product development and market access.
While facing challenges related to compliance, market dynamics, and competitive landscape, the company is well-positioned for international expansion and future growth.
By capitalizing on strengths in commercial strategies, pipeline progress, and revenue diversification, Krystal Biotech can navigate challenges and seize opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative Dermatology (SID) Annual Meeting in May 2020

Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress

Krystal Biotech: Revisiting This Gene Therapy Pioneer Ahead Of Q2 Data

PITTSBURGH, Jan.  24, 2020  (GLOBE NEWSWIRE) --  Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, announced today the ground breaking of the second commercial gene therapy facility in Findlay Township, Pennsylvania. The Findlay-based Current Good Manufacturing Practice (cGMP) facility, named ASTRA, will have the capacity to produce commercial gene therapy medicines to treat patients suffering from debilitating rare diseases. The ground-breaking ceremony is being held today, January 24, 2020.  

Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility

PITTSBURGH, Jan.  21, 2020  (GLOBE NEWSWIRE) --  Krystal Biotech , Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, today announced the appointment of Jennifer Chien to the newly created position of chief commercial officer, effective January 20, 2020. Ms. Chien has more than 20 years of commercial leadership experience in the biopharmaceutical industry, most recently having served as vice president, head of genetic diseases at Sanofi Genzyme. 

Krystal Biotech Appoints Jennifer Chien as Chief Commercial Officer

As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).

Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue?

Axsome Therapeutics

Kodiak Sciences Inc

Despite soaring already, these biotech stocks aren't finished climbing.

3 Biotech Stock Rockets With More Fuel in the Tank

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors?

Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to Buy

PITTSBURGH, Sept.  27, 2019  (GLOBE NEWSWIRE) --  Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, announced the granting of a new patent for its lead product candidate KB103 after receiving a Notice of Acceptance from IP Australia for patent application number 2016401692. This represents the company’s first foreign patent and a Notice of Acceptance will appear in the Australian Official Journal of Patents on October 3, 2019.

Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent

Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be market disruptive.

Krystal Clear: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin Disease

Krystal Biotech: KB-103 Sprints To Become The First Approved Topical Gene Therapy For Skin Disease

PITTSBURGH, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI).  The study, termed GEM-3 study, will examine KB105, an HSV-1 based gene therapy engineered to deliver a human TGM1 gene, in patients with ARCI.

Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 (“TGM1”) Deficient Autosomal Recessive Congenital Ichthyosis (“ARCI”)

PITTSBURGH, Aug.  27, 2019  (GLOBE NEWSWIRE) --  Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chief executive officer, will be at the upcoming Citi’s 14th Annual Biotech Conference being held on September 4-5, 2019 at the Four Seasons Boston.

Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference

Dova Pharma

MeiraGTx Holdings plc

It was a great week for these three stocks, but can they continue climbing?

3 Small-Cap Biotech Stocks That Soared Last Week

Krystal Biotech Inc (NASDAQ: KRYS) announced positive Phase 2 data for KB103 Monday and said the gene therapy received the Regenerative Medicine Advanced Therapy designation from the FDA.

Krystal Biotech Analyst Lifts Price Target More Than 50% On Positive Phase 2 Data, RMAT Designation

In recent Krystal Biotech news, KRYS stock is soaring as the company's drug designed to treat a skin condition received expedited FDA review.
The post Krystal Biotech News: Why Is KRYS Stock Soaring Today?

Krystal Biotech News: Why Is KRYS Stock Soaring Today?

Krystal Biotech Inc (NASDAQ: KRYS) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday.

Krystal Biotech Rallies On Positive Trial Results For Skin Condition

Shares of Krystal Biotech Inc. were up 27% in Monday intraday trade after the gene therapy company said it had received an expedited review designation from the FDA for its lead drug candidate to treat a skin condition called dystrophic epidermolysis bullosa.

Krystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDA

BioMarin Pharmaceutical

Dicerna Pharmaceuticals

Global Blood Therapeutics

Iovance Biotherapeutics

We are now approaching the second half of 2019. And it may be time for a little portfolio rebalancing.

5 Strong Buy Biotech Stocks for the Second Half

Krystal Biotech Inc. is a clinical-stage gene therapy company based in Pittsburgh, PA, which is founded in 2015 and has its IPO in September 2017.

News for Krystal Biotech Stock (KRYS)